SME Times is powered by   
Search News
Just in:   • Equity indices break two-day losing streak on value buying  • IMF urges Sri Lanka to tighten monetary policy  • Global semiconductor sales to reach $676 bn this year: Gartner  • Tinna Rubber hits upper circuit, investors accumulate 900% returns in year  • Availability of jobs in Japan improves for 1st time in 3 yrs 
Last updated: 18 Sep, 2017  

MedTech Presents Recommendations for 'Ease of Doing Business'

NewsVoir | 18 Sep, 2017
The Medical Technology Association of India (MTaI) held its maiden MedTech Summit in New Delhi. The first-of-its kind Summit brought together the unique and much needed interface of policy makers, Industry, doctors with the patients. Key departments and ministries such as the Ministry of Commerce and Industry, Department of Health and Family Welfare, and the NITI Aayog were represented at the Summit. The medical technology industry was represented by top MedTech companies including inter alia Abbott Vascular, Alcon, Bard, Bausch & Lomb, Boston Scientific, Johnson & Johnson, KARL STORZ, Medtronic, Olympus, Terumo, and Vygon India.

The MedTech Summit put forward some key asks and recommendations for the consideration of the policy makers that would pave the way for a more enabling environment for the industry. The Summit was kicked off with an address by Mr. Pavan Choudary, Director General, MTaI. He said, “The healthcare sector rests on four pillars – Hospitals, Pharmaceutical industry, Health Insurance industry and the MedTech industry. The last of these is the least understood of all yet most significant for enhancing quality of healthcare, and has direct implications for patient outcomes. This implores the need for more nuanced approaches in policymaking for the sector. The sector needs to be uncovered and it is the patient who should do the unveiling, which is what the aim of this Summit is.”


In view of recent policy changes in the medical technology space, the industry stressed on the need for the sub-sectoring and sub-categorization of medical devices on the basis of the engineering complexity, for policy and decision clarity.


Import substitution as a focus of policies needs to be replaced with greater efforts directed towards ensuring global competitiveness through export promotion and meeting global quality standards. The recently presented NITI Aayog action agenda recognizes the significance of global companies’ presence for the domestic industry to compete with and grow.


Make in India, a noble initiative, should however be implemented in a phased manner. It must focus on the devices that have the potential to be made locally in the short run, instead of the advanced technologies that require a more enhanced ecosystem and know-how that may take years to develop in the country.


This means that policies must factor in the existing gaps in the domestic manufacturing industry, and promote ease of doing business by way of reduced inter-organizational delays, enhanced startup industrial finance, simplified regulations such as single-window clearance, and greater investment in infrastructure. Mr. Sanjay Bhutani, Director, MTaI asserted, “The industry continues to be largely under- understood and under prioritized.”


Another key recommendation put forth at the Summit was to expand the bed capacity in the country. This is particularly crucial given the rising burden of diseases in the country today and the lack of access to quality healthcare. Many pockets of the country remain underserved, and are calling out for real-time scaling up of solutions to address this demand. The expansion of the healthcare delivery system will automatically provide an impetus for the medical devices market to grow.


Further, for long term advantage, infrastructural development and fiscal incentives are needed to keep the wheels of innovation and R&D rolling. This will simultaneously help achieve the twin objectives of greater patient access as well as the availability of latest and high-quality technology.


“The medtech industry should voluntarily help the government correct the price anomalies in the market. And the government should stay away from price control which can skew the sector and affect healthcare in worse ways,” said Mr. Gautam Chikermane, Vice President, Observer Research Foundation (ORF).


MTaI endorses the Trade Margin Rationalization Report of the Department of Pharmaceuticals, provided unique and deserving sub-sectoral nuances are given due consideration.


Any access enhancing (price control) mechanisms must be preceded by a careful impact analysis on creation of geographical access barriers, on quality of outcomes, reverse medical tourism, and decreased incentive to innovate. Speaking in the session on ‘Orthopaedic Implants’, Dr. Shekhar Agarwal, Chief Surgeon, Delhi Institute of Trauma & Orthopaedics, Sant Parmanand Hospital said, “A patient may compromise on the surgeon’s fee and the quality of hospital room, but seldom on the quality of the medical device. Multinational companies have made significant training and capacity building efforts among healthcare workers in the country in the last few decades. Detracting from the progress made in the MedTech space will only set us back by decades.”

“There is a need to look at medical devices holistically, and not through narrow prisms of singular initiatives and policies,” said Urvashi Prasad, Public Policy Specialist, Office of Vice Chairman, NITI Aayog. There is a significant gap in the availability of data in the public domain for the policy maker to understand the sector better and in a more nuanced manner. Hospitals which collect and analyze data need to make them public. “It is imperative for hospitals to be transparent in order for the healthcare sector to be more outcome-oriented,” said Dr. Dinesh Jain, Vice President – Clinical Data Analytics, Max Hospital.


The Summit included insightful conversations in sessions on cardiovascular, ophthalmology, orthopaedic implants, critical care, endoscopic interventions, and more. In summary, the key asks of the industry from the policymakers included the sub-sectoring and sub-categorization of medical devices, global competitiveness, ease of doing business, infrastructural development and fiscal incentives, expansion of the bed capacity in the country, and recognizing sub-sectoral nuances in the Trade Margin Rationalization Report.


Mr. Diwaker Rana, Chairman, MTaI MedTech Summit, said, “At the Summit today, the patients’ perspective reaffirmed how important medical technology and the quality of medical device are for transforming lives, and the physicians’ perspective reiterated the importance of training in the adoption of medical technology for better outcomes.”


About MTaI

Medical Technology Association of India (MTaI – pronounced as Em-tai) is a not-for-profit organization duly registered under sub-section (2) of section 7 of the Companies Act, 2013 and Rule 8 of the Companies (Incorporation) Rules, 2014.


MTaI is an association of research-based medical technology companies who have made remarkable investments by setting up a large number of R&D centres and manufacturing plants in India. MTaI represents a wide spectrum of the medical device and equipment industry with global experience in innovation and manufacturing. All the time stressing on the three hallmarks of healthcare - Quality, Consistency and Patient Safety, MTaI wants to be a responsible voice of the industry. The association is committed to improving access to affordable and quality healthcare for patients.


MTaI looks to partner with the Government of India in setting a roadmap for the growth of medical devices industry by bringing in even bigger investments through technology upgradation and knowledge dissemination in the provider space. This will be achieved through the active participation of the industry that can contribute towards furthering FDI and the government’s ‘Make in India’ initiative.


For more information on MTaI, Please visit our Website:


[1] The partners for the Summit included: Johnson & Johnson Vision, KARL STORZ, Medtronic, Terumo, Olympus, 3M, BARD, Johnson & Johnson Medical Companies, Liva Nova, Smiths Medical, Alcon, Bausch & Lomb, Braun, Boston Scientific, COOK Medical, Edwards Life Sciences, Hoya Surgical Optics, Molnlycke Healthcare, Vygon India.

Print the Page Add to Favorite
Share this on :

Please comment on this story:
Subject :
(Maximum 1500 characters)  Characters left 1500
Your name:

  Customs Exchange Rates
Currency Import Export
US Dollar
UK Pound
Japanese Yen 58.85 56.85
As on 27 Apr, 2022
  Daily Poll
COVID-19 has directly affected your business
 Can't say
  Commented Stories
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter